Last reviewed · How we verify
NCT05842551
Prismatic Lenses and tDCS in Neglect
NA trial testing Prismatic adaptation and electric stimulation in Stroke, Ischemic in 30 participants. Currently enrolling.
15 July 2026
Quick facts
| Lead sponsor | Istituti Clinici Scientifici Maugeri SpA |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 7 March 2023 |
| Primary completion | 15 July 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Prismatic adaptation and electric stimulation
Conditions studied
- Stroke, Ischemic — all drugs for Stroke, Ischemic →
Sponsor
Istituti Clinici Scientifici Maugeri SpA
Who can join
Adults 18 to 90, any sex, with Stroke, Ischemic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to to evaluate the effect and feasibility of a rehabilitation protocol with prismatic lenses associated with tDCS, compared to a prismatic lens rehabilitation protocol associated with sham stimulation, in reducing the signs of neglect in a group of patients with spatial heminegligence following ischemic stroke of the right hemisphere. The secondary objective is to evaluate the impact of this rehabilitation protocol on functional outcome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05842551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stroke, Ischemic
Currently open trials in the same condition.
- NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
- NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
- NCT07282041 — Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis · Phase 2, PHASE3 · recruiting
- NCT07135089 — Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban · Phase 3 · recruiting
- NCT07047014 — Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ische · Phase 3 · recruiting
Other Istituti Clinici Scientifici Maugeri SpA trials
Trials by the same sponsor.
- NCT07521436 — Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and Men · not yet recruiting
- NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
- NCT07448181 — Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema · recruiting
- NCT07432204 — Therapeutic Music Listening in Post Stroke Patients. · NA · recruiting
- NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05842551 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituti Clinici Scientifici Maugeri SpA
- Last refreshed: 8 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05842551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing